Who Owns Arcus Biosciences Stock?
NYSE: RCUSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 74.92%
- Institutions (% of float)
- 105.21%
- Held by insiders
- 28.80%
- Institutional holders
- 330
- Institutions 71.2%
- Insiders 28.8%
- Public and other 0.0%
Who owns Arcus Biosciences stock?
Institutional investors own about 74.9% of Arcus Biosciences's shares, spread across 330 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 28.80% of RCUS.
The largest institutional holders are Gilead Sciences Inc (24.68%), Blackrock Inc. (12.89%) and State Street Corporation (4.74%). Together, the top 10 institutions control 65.3% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their RCUS positions and 3 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of RCUS
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Gilead Sciences Inc | 31.42M | 24.68% | 0.0% |
| Blackrock Inc. | 16.42M | 12.89% | +7.8% |
| State Street Corporation | 6.03M | 4.74% | +11.4% |
| Wellington Management Group, LLP | 5.90M | 4.63% | -3.2% |
| Montanova Capital LLC | 4.78M | 3.75% | -5.1% |
| Vanguard Portfolio Management LLC | 4.48M | 3.51% | +4.8% |
| FMR, LLC | 4.05M | 3.18% | +247.5% |
| Vanguard Capital Management LLC | 3.89M | 3.05% | +0.8% |
| Citadel Advisors Llc | 3.14M | 2.46% | +135.7% |
| Woodline Partners LP | 3.01M | 2.36% | -20.4% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of RCUS
| Fund | Shares | % Held |
|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.29M | 4.15% |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 3.45M | 2.71% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.80M | 2.20% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.72M | 2.14% |
| iShares Trust-iShares Russell 2000 ETF | 2.27M | 1.78% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.01M | 0.79% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.00M | 0.79% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 978.27K | 0.77% |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 852.70K | 0.67% |
| SPDR SERIES TRUST-State Street SPDR Portfolio S&P 600 Small Cap ETF | 813.36K | 0.64% |
Frequently asked questions
Who is the largest shareholder of Arcus Biosciences?
Gilead Sciences Inc is the largest institutional shareholder of RCUS, owning 24.68% of shares outstanding (31.42M shares) as of its latest 13F filing.
What percentage of Arcus Biosciences is owned by institutions?
Institutions own about 74.9% of RCUS shares and 105.2% of the public float.
How much of Arcus Biosciences do insiders own?
Insiders, such as officers and directors, own about 28.80% of RCUS shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.